Search results
Showing 1 to 11 of 11 results for clobazam
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.
This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.
Show all sections
Sections for NG217
- Overview
- 1 Diagnosis and assessment of epilepsy
- 2 Information and support
- 3 Referral to tertiary specialist services
- 4 Principles of treatment, safety, monitoring and withdrawal
- 5 Treating epileptic seizures in children, young people and adults
- 6 Treating childhood-onset epilepsies
- 7 Treating status epilepticus, repeated or cluster seizures, and prolonged seizures
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Alcohol-use disorders: diagnosis and management of physical complications (CG100)
This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.
New life-changing treatment option recommended for type of rare epilepsy
This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.